40th week of 2010 patent applcation highlights part 36 |
Patent application number | Title | Published |
20100254956 | PROBIOTIC BACTERIA AND REGULATION OF FAT STORAGE - The present invention provides methods for manufacturing heat treated products involving the use of probiotic bacteria, e.g. lactic acid bacteria and/or Bifidobacteria, cultures of such bacteria, supernatant from such cultures, and/or concentrates of such supernatant and/or fractions of such supernatant. The invention further provides heat treated products of such processes and their use for regulation of cellular uptake of fat and/or triglycerides and/or body weight management or weight reduction and/or redistribution of fat and/or reduction in visceral and/or abdominal fat deposition in a subject. | 2010-10-07 |
20100254957 | GROWTH MEDIA AND SAPROPHYTIC USE FOR PICHIA ANOMALA - A biologically pure culture of a yeast of the species | 2010-10-07 |
20100254958 | Antigen-Specific T-Cell Preparations from Bone Marrow - A method for the generation of antigen-specific T-cell preparations for adoptive therapy is provided, comprising the steps of obtaining lymphoid cells from the bone marrow of a patient in a first step, expanding the lymphoid cells in cell culture medium ex-vivo in the presence of at least one of IL2 and IL7 and or more antigens, yielding a T-cell preparation, and isolating the T-cell preparation from the culture medium in an isolation step. T-cell preparations provided according to the inventive method, and the use of such T-cell preparations for the treatment of infectious disease and cancer is also provided. | 2010-10-07 |
20100254959 | NAPHTHALENE ISOXAZOLINE INVERTEBRATE PEST CONTROL AGENTS - Disclosed are compounds of Formula 1, | 2010-10-07 |
20100254960 | NAPHTHALENE ISOXAZOLINE COMPOUNDS FOR CONTROL OF INVERTEBRATE PESTS - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, | 2010-10-07 |
20100254961 | WATER-SOLUBLE ELECTROSPUN SHEET - A water-soluble electrospun sheet, containing a water-soluble base material made of at least one material selected from a group consisting of: high-molecular proteins and decomposition products thereof; cellulose-based polymers; plant-based polymers and decomposition products thereof; vinyl-based polymers; acrylic-based polymers; and water-soluble polysaccharides; is provided. In addition to the water-soluble base material, the sheet may further contain at least one functional component selected from among: emulsifying components; stabilizing components; antimicrobial components; humectant components; skin-whitening components; anti-ultraviolet components; astringent components; keratin-softening components; anti-inflammatory components; and coloring components. | 2010-10-07 |
20100254962 | FUNCTIONAL DRINK - The invention relates to a liquid food product as aqueous solution with anti-ageing effect, which comprises resveratrole, citric acid, fructose, black grape polyphenol extract, green tea extract, vitamin E, vitamin C and niacin. A concentrated juice from red, edible soft fruit is present at least in a sufficient amount to impart the taste, and advantageously the colour, of the formulation. | 2010-10-07 |
20100254963 | PEG-MODIFIED ARGININE/LYSINE OXIDOREDUCTASE - The present invention is directed to an arginine/lysine oxidoreductase modified with polyethylene glycol and to a production method thereof and to methods of treating disorders responsive to a modification of amino acid levels reactive oxygen species and/or ammonium. | 2010-10-07 |
20100254964 | Modified Bouganin Proteins, Cytotoxins and Methods and Uses Thereof - The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer. | 2010-10-07 |
20100254966 | TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE II - Methods of treating glycogen storage disease type II, by administering acid α-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II. | 2010-10-07 |
20100254967 | METHODS AND MATERIALS FOR REDUCING BIOFILMS - This document provides methods and materials related to reducing biofilms. For example, enzymes (e.g., glycosyl hydrolases), nucleic acid molecules encoding enzymes, host cells containing nucleic acid encoding enzymes, and methods for using enzymes to reduce biofilms and infections associated with biofilms are provided. | 2010-10-07 |
20100254968 | PHARMACEUTICAL PREPARATION FOR TREATING BENIGN PROSTATIC HYPERPLASIA - The present invention relates to the use of at least one protease for the manufacture of a medicament for the treatment and/or prevention of benign prostate hypertrophy/hyperplasia, wherein the medicament is adapted for enteral administration, the at least one protease is selected from the group consisting of plant, non-mammalian animal and microbial proteases and the at least one protease is administered in an amount of 1 to 100 mg/kg body weight. | 2010-10-07 |
20100254969 | Cosmetic Composition For Exfoliating Skin Keratin - The present invention relates to a cosmetic composition containing enzymes, and more particularly to a cosmetic composition, which contains, as active ingredients, 1) papain, and 2) at least one selected from the group consisting of theanine and N-acetyl glucosamine, and thus functions to control the skin turnover cycle and promote the exfoliation of skin keratin. | 2010-10-07 |
20100254970 | NGAL FOR REDUCTION AND AMELIORATION OF ISCHEMIC AND NEPHROTOXIC INJURIES - Use of neutrophil gelatinase-associated lipocalin (NGAL) as a therapeutic and in a method of treating, reducing, or ameliorating an injury selected from an ischemic injury, an ischemic-reperfusion injury, and a toxin-induced injury, to an organ in a patient. The invention includes administering to the patient NGAL in an amount effective to treat, reduce or ameliorate ischemic, ischemic-reperfusion, or toxin-induced injury to the organ, such as the kidney. A siderophore can be co-administered with the NGAL. The invention also relates to administering a sideophore to enhance a response to secretion of NGAL following an ischemic or toxin-induced injury to an organ in a patient. | 2010-10-07 |
20100254971 | Method for Diagnosing Prognosing Inflammatory Bowel Disease and Crohn's Disease - Disclosed are methods for diagnosing and prognosing Inflammatory Bowel disease or Crohn's disease (CD) by measuring levels of antibodies to glycans in a biological sample. | 2010-10-07 |
20100254972 | METHODS FOR SELECTING PROTEASE RESISTANT POLYPEPTIDES - The invention relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the GI tract or pulmonary tissue of a human. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, combining the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, eg for treating disease or conditions of GI tract or pulmonary tissue in humans. | 2010-10-07 |
20100254973 | Materials and Methods for Diagnosis of Asthma - The present invention pertains to materials and methods for diagnosing and/or determining the prognosis and likelihood of developing asthma. In one embodiment, methods of the invention comprise the use of single nucleotide polymorphic markers of asthma. Markers of the invention are present in the atria natriuretic peptide (NPPA) gene, and serve as a marker for genetic susceptibility of a person or animal in developing asthma. | 2010-10-07 |
20100254974 | Modulation of Immunostimulatory Properties of Oligonucleotide-Based Compounds by Optimal Presentation of 5' Ends - The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers of the invention comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunostimulatory oligonucleotide and having an accessible 5′ end. | 2010-10-07 |
20100254975 | ALPHA-4 BETA-7 HETERODIMER SPECIFIC - There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them. | 2010-10-07 |
20100254976 | USE OF PROTEASE NEXIN 1 INHIBITORS TO REDUCE METASTASIS - The present invention relates to a method of inhibiting metastasis comprising the administration of an inhibitor of protease nexin-1 (PN-1), characterized in that said inhibitor is administered at a therapeutical dosage that does not completely inhibit the expression and/or activity of PN-1. | 2010-10-07 |
20100254977 | ENGINEERED ANTI-ALPHA V-INTEGRIN HYBRID ANTIBODIES - The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents. | 2010-10-07 |
20100254978 | ANTIBODY MOLECULES HAVING SPECIFICITY FOR HUMAN OX40 - The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules. | 2010-10-07 |
20100254979 | Humanized PAI-1 Antibodies and Uses Thereof - The present application relates to compositions of humanized anti-PAI-1 antibodies and antigen-binding fragments thereof which convert PAI-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind and neutralize PAI-1 by converting PAI-1 to its latent form or increasing proteolytic cleavage. Another aspect relates to the use of humanized antibodies which inhibit or neutralize PAI-1 for the detection, diagnosis or treatment of a disease or condition associated with PAI-1 or a combination thereof. | 2010-10-07 |
20100254980 | MOLECULES AND METHODS FOR MODULATING LOW-DENSITY-LIPOPROTEIN RECEPTOR-RELATED PROTEIN 6 (LRP6) - The invention discloses LRP6 agonizing or antagonizing binding molecules (e.g., antibodies or a Fab fragments), and their use to facilitate or inhibit Wnt pathway signaling, respectively. Said LRP6 agonizing or antagonizing binding molecules can be used to e.g., diagnose, ameliorate the symptoms of, protect against, and treat Wnt signaling disorders associated with aberrantly low or aberrantly high levels of Wnt pathway signaling, respectively. Non-limiting examples of disorders which can be treated associated with aberrant upregulation of Wnt signaling is cancer (e.g., colon cancer). Non-limiting examples of disorders which can be diagnosed, protected against, and treated include cancers, bone disorders (e.g., osteoporosis and osteoarthritis), diabetes, neurodegenerative diseases such as Alzheimer's disease, and fibrotic disorders. | 2010-10-07 |
20100254981 | Secreted/Cell Bound Poxvirus Proteins and Methods of Use Thereof as Vaccines and Anti-Viral Agents - Compositions and methods for the treatment and prevention of pox virus infections are disclosed. | 2010-10-07 |
20100254982 | CANCER SPECIFIC ANTIBODY AND CELL SURFACE PROTEINS - The present invention provides the amino acid and nucleic acid sequences of heavy chain and light chain complementarity determining regions of a cancer specific antibody. In addition, the invention provides cancer specific antibodies and immunoconjugates comprising the cancer specific antibody attached to a toxin or label, and methods and uses thereof. The invention also relates to diagnostic methods and kits using the cancer specific antibodies of the invention. Further, the invention provides a novel cancer-associated antigen and its uses thereof. | 2010-10-07 |
20100254983 | USES OF RAGE ANTAGONISTS FOR TREATING OBESITY AND RELATED DISEASES - This invention provides a method for treating obesity in which comprises administering to the subject an antagonist of a receptor for advanced glycation end products (RAGE) in an amount effective to inhibit binding of a ligand of RAGE to RAGE so as to thereby treat obesity in the subject. The present invention also provides a method for treating hyperglycemia and increased cholesterol, insulin, triglyceride and leptin levels comprising administering to the subject an antagonist of RAGE in an amount effective to inhibit binding of a ligand of RAGE to RAGE so as to thereby treat hyperglycemia and lower cholesterol, insulin, triglyceride and leptin levels on the subject. | 2010-10-07 |
20100254984 | FUSION CONSTRUCTS CONTAINING ACTIVE SECTIONS OF TNF LIGANDS - Disclosed is a recombinant fusion protein containing an amino-acid sequence which comprises: (a) the Fc section or part of an Fc section of an immunoglobulin as component (A) or a functional variant of component (A); (b) the extracellular part of a TNF ligand or a partial sequence of the extracellular part of a TNF ligand as component (B) or a functional variant of component (B); and optionally (c) a transition area between component (A) and component (B), containing a linker. | 2010-10-07 |
20100254985 | Protein Formulations - The present invention provides formulations of proteins comprising a variant Fc region that improve the stability in part by reducing the propensisty of such molecules to rapidly aggregate. The invention provides both liquid and lyophilized formulations either of which can be utilized to generate a high protein concentration liquid suitable for administration to a subject. The invention further provides methods of utilizing the formulations of the present invention for therapeutic or prophylactic treatment of diseases and disorders or for diagnostic purposes. | 2010-10-07 |
20100254986 | METHOD FOR MAKING HETEROMULTIMERIC POLYPEPTIDES - The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the interface of a second polypeptide, such that the protuberance can be positioned in the cavity so as to promote heteromultimer formation and hinder homomultimer formation. “Protuberances” are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the protuberances are created in the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis. | 2010-10-07 |
20100254987 | ENGINEERED PROTEINS WITH HIGH AFFINITY FOR DOTA CHELATES - The present invention features, inter alia, compositions and methods for the treatment of cancer and infectious disease. The compositions include engineered proteins that specifically bind a metal chelate and may be bispecific. For example, the engineered proteins may bind (a) a target (e.g., a cellular protein) on a cancerous cell or a pathogen and (b) a metal chelate comprising DOTA, or an active variant thereof, and a metal ion such as a radionuclide. By virtue of the multiple binding sites, the engineered protein effectively delivers a metal chelate to a cell one wishes to destroy. | 2010-10-07 |
20100254988 | Bispecific Anti ErbB2 / Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-2 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 2010-10-07 |
20100254989 | Bispecific Anti ErbB1 / Anti c Met Antibodies - The present invention relates to bispecific antibodies against human ErbB-1 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 2010-10-07 |
20100254990 | ANTI-NGF ANTIBODIES FOR THE TREATMENT OF VARIOUS DISORDERS - The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including asthma, arthritis and psoriasis. The methods are effective in treating these disorder in a patient without having a significant adverse effect on the immune system of the patient. | 2010-10-07 |
20100254991 | Use of Cytokine Expression to Predict Skin Inflammation; Methods of Treatment - Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23. | 2010-10-07 |
20100254992 | ANTI-MCP-1 ANTIBODIES, COMPOSITIONS, METHODS AND USES - The present invention relates to at least one novel anti-MCP-1 antibody having specific epitopes, including isolated nucleic acids that encode at least one anti-MCP-1 antibody, MCP-1, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices. | 2010-10-07 |
20100254993 | HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN IL-4 - Antibodies which are specific for human interleukin-4 and their use in the treatment of IL-4 and/or IgE mediated diseases. | 2010-10-07 |
20100254994 | Compositions and Methods for Binding or Inactivating Ghrelin - The present invention relates, in part, to agents for binding and/or inactivating native ghrelin. These agents include those that specifically bind and/or cleave octanoylated native ghrelin. Such agents include antibodies and enzymes. The agents also include those that can be used to generate antibodies that specifically hind and/or cleave octanoylated native ghrelin. Compositions that include the agents are also provided. Further provided are methods of producing and using the agents and compositions thereof. For instance, the agents and compositions can be used to reduce or eliminate the hunger response activity of octanoylated native ghrelin. Therefore, the agents, compositions and methods provided can be used to suppress appetite and/or treat obesity. In addition, the agents, compositions and methods can be used to treat any disease associated with or caused by ghrelin (e.g., Prader-Willi Syndrome). | 2010-10-07 |
20100254995 | POLYPEPTIDES, ANTIBODY VARIABLE DOMAINS AND ANTAGONISTS - The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis. | 2010-10-07 |
20100254996 | SYNERGISTIC TREATMENT OF CELLS THAT EXPRESS EPHA2 AND ERBB2 - The present invention relates to methods of treating hyperproliferative cells that express EphA2 and ErbB2. The present invention further relates to methods of selecting patient populations for treatment methodologies. | 2010-10-07 |
20100254997 | ADAMTS4 as a blood biomarker and therapeutic target for chronic renal failure - ADAMTS4 is found to be useful as a blood biomarker for chronic renal failure and also as a therapeutic target for treating chronic renal failure in a human individual. A change in the level of expression of selected genes as disclosed herein in kidney tissue of an individual may also be used to diagnose chronic renal failure in an individual. | 2010-10-07 |
20100254998 | METHOD FOR PROLONGING LONGEVITY - The present application relates to a method for increasing the longevity of a subject by modulating a non-insulin-like neuropeptide receptor pathway. Preferably, said non-insulin-like neuropeptide receptor is the neuromedin U receptor 1 (NMUR1). | 2010-10-07 |
20100254999 | EG-VEGF NUCLEIC ACIDS AND POLYPEPTIDES AND METHODS OF USE - The present invention is directed to novel polypeptides designated herein as EG-VEGF and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Also provided herein are methods of screening for modulators of EG-VEGF. Furthermore, methods and related methods of treatment are described herein which pertain to regulating cellular proliferation and chemotaxis. | 2010-10-07 |
20100255000 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME - The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor. | 2010-10-07 |
20100255001 | BLOCKERS OF SEROTONIN AND ITS RECEPTORS FOR THE TREATMENT OF HEPATITIS - The present invention relates to a method of treating hepatitis comprising administering a serotonin blocker, and the use of such blockers in said treatment and in the manufacture of medicaments for treating hepatitis. | 2010-10-07 |
20100255002 | Immunogenic compositions for chlamydia trachomatis - The invention relates to compositions comprising combinations of | 2010-10-07 |
20100255003 | Immune Disease Medicament Comprising a Modulator of the Binding Between a Heparin Bindin Domain of Thrombospondin-1 and a Beta1 Integrin - An article of manufacture comprising packaging material and a pharmaceutical composition is disclosed, the article of manufacture being identified in print in or on the packaging material for treatment of an immunity-related disease in a subject in need thereof. The pharmaceutical composition comprises a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of modulating an interaction between a heparin-binding domain of a thrombospondin and a receptor of the heparin-binding domain. | 2010-10-07 |
20100255004 | RECEPTOR TYROSINE KINASE PROFILING - The invention provides novel methods for designing and administering therapeutic treatments for subjects afflicted with cancer. One aspect provides methods of identifying RTK pathways in a cancer and formulating treatment plans based on a plurality of RTK inhibitors. The invention further provides methods for evaluating candidate tyrosine kinase inhibitors for therapeutic efficacy. | 2010-10-07 |
20100255005 | GAMMA SECRETASE MODULATORS - In its many embodiments, the present invention provides a novel class of heterocyclic compounds as modulators of gamma secretase, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the central nervous system using such compounds or pharmaceutical compositions. | 2010-10-07 |
20100255006 | NOVEL MOLECULES OF THE PYRIN/NBS/LRR PROTEIN FAMILY AND USES THEREOF - Novel PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 proteins, the invention further provides PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 fusion proteins, antigenic peptides and anti-PYRIN-2, -PYRIN-3, -PYRIN-5, -PYRIN-6, -PYRIN-7, -PYRIN-8, -PYRIN-10, and -PYRIN-11 antibodies. The invention also provides PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, and PYRIN-11 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a PYRIN-2, PYRIN-3, PYRIN-5, PYRIN-6, PYRIN-7, PYRIN-8, PYRIN-10, or PYRIN-11 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 2010-10-07 |
20100255007 | THERAPEUTIC AGENTS FOR GRAFT-VERSUS-HOST DISEASE COMPRISING INTERLEUKIN 6 RECEPTOR INHIBITOR AS ACTIVE INGREDIENT - The present invention provides a novel therapeutic agent for graft-versus-host disease (GVHD). | 2010-10-07 |
20100255008 | ANTIBODIES AGAINST HUMAN TWEAK AND USES THEREOF - An antibody binding to TWEAK comprising as heavy chain variable domain a CDR3H selected from the group consisting of SEQ ID NO: 8, 16 or 24. | 2010-10-07 |
20100255009 | Methods for Inducing Mixed Donor-Recipient Chimerism in an Allograft Transplant Recipient - A method is provided for obtaining mixed donor-recipient chimeric cells, comprising the steps of (a) administering to an allograft recipient a short-term immunosuppressive regimen that depletes about 50% to about 99.9% of recipient T cells circulating in the peripheral blood of the recipient; (b) implanting an allograft from a donor into the recipient; (c) allowing the development of mixed donor-recipient chimeric cells in the recipient after completion of the immunosuppressive regimen; and (d) harvesting the chimeric cells from the recipient. The invention further provides method for compiling a library of chimeric cells and using the library to select of chimeric cells for the induction of tolerance to an allograft in a naïve or previously transplanted recipient. | 2010-10-07 |
20100255010 | ANTI-HER ANTIBODIES - The invention provides anti-HER antibodies, including multispecific anti-HER antibodies, compositions comprising and methods of using these antibodies. Also provided herein are EGFR/HER3 multispecific antibodies that are less toxic than traditional EGFR antagonists. | 2010-10-07 |
20100255011 | COMPOSITIONS AND METHODS FOR MODULATING THE ACTIVITY OF COMPLEMENT REGULATORY PROTEINS ON TARGET CELLS - This invention relates to agents capable of reducing the activity, amount or density of complement regulatory proteins (CRPs) on target cells. The invention also provides methods of identification of such agents, methods of making, and uses thereof. | 2010-10-07 |
20100255012 | RECOMBINANT FUCOSE MODIFIED MONOVALENT HALF-ANTIBODIES OBTAINED BY MOLECULAR ENGINEERING - Glycosylated monovalent antibodies binding to selected antigens with a low or lacking fucose content, which are capable of inducing antibody dependent cellular cytotoxicity (ADCC) on cells expressing the selected antigens in the presence of effector cells, methods for producing the monovalent antibodies, pharmaceutical compositions comprising such monovalent antibodies and use thereof for different diagnostic and therapeutic applications. | 2010-10-07 |
20100255013 | GLYCOPROTEIN COMPOSITIONS - The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin. | 2010-10-07 |
20100255014 | Protein Complex Using An Immunoglobulin Fragment and Method For The Preparation Thereof - Disclosed are a protein conjugate with improved in vivo duration and stability and the use thereof. The protein conjugate includes a physiologically active polypeptide, a non-peptide polymer and an immunoglobulin Fc fragment. Since the three components are covalently linked, the protein conjugate has extended in vivo duration and enhanced stability for the physiologically active polypeptide. The protein conjugate maintains the in vivo activity at relatively high levels and remarkably increases the serum half-life for the physiologically active polypeptide, with less risk of inducing undesirable immune responses. Thus, the protein conjugate is useful for developing long-acting formulations of various polypeptide drugs. | 2010-10-07 |
20100255015 | PHARMACEUTICALS COMPOSITIONS COMPRISING ACTINOMYCETE GLYCEROL ACYL DERIVATIVES ANTIGENS, THEIR PROCESS OF EXTRACTION, AND THEIR USE AGAINST TUBERCULOSIS - The present invention relates to the therapeutic use of actinomycete glycerol monomycolate derivatives as antigens, their process of extraction, and their use in the treatment or the prophylaxis of tuberculosis. | 2010-10-07 |
20100255016 | Absorbable crystalline polyether-ester-urethane-based bioactive luminal liner compositions - Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty. | 2010-10-07 |
20100255017 | PURIFIED HEMOCYANIN OBTAINED FROM FISSURELLA LATIMARGINATA, FISSURELLA CUMINGI OR FISSURELLA MAXIMA; SUBUNIT OF PURIFIED HEMOCYANIN; USE OF HEMOCYANIN, ITS SUBUNIT OR IMMUNOGENIC FRAGMENTS AND COMPOSITIONS CONTAINING THE SAME - The invention relates to purified hemocyanins, subunits or immunogenic fragments thereof, wherein the hemocyanins are purified from a hemolymph of | 2010-10-07 |
20100255018 | POLYNUCLEOTIDES AND POLYPEPTIDES INVOLVED IN GESTATIONAL MALARIA, AND BIOLOGICAL APPLICATIONS - The present invention relates to novel antigens involved in gestational malaria, and more particularly to polynucleotide and polypeptide sequences, conjugates, cloning vectors including said sequences for the preparation of immunogenic compositions and vaccines, antibodies, and to the use thereof for treating gestational malaria. The invention also relates to diagnostic methods and kits. | 2010-10-07 |
20100255019 | Ii-KEY/HER-2/NEU HYBRID CANCER VACCINE - Provided are methods and compositions for treating cancer in humans, the cancer being characterized by expression of Her-2/neu. The methods involve vaccinating a patient with an Ii-Key/MHC class II hybrid construct and thereby stimulating an immune response to the native Her-2/neu protein. The construct may be in the form of an Ii-Key hybrid peptide or a nucleic acid encoding an Ii-Key hybrid peptide. Methods are described wherein the cancer being treated is breast cancer. Also claimed is a pharmaceutical composition comprising an Ii-Key/MHC class II hybrid construct with and without an adjuvant. The adjuvant can include GM-CSF. The Ii-Key hybrid construct includes the LRMK [SEQ ID NO.: 2] residues of Ii-Key protein and an MHC Class II epitope of a protein or portion thereof which is used in the vaccine or a DNA encoding the same hybrid peptide. | 2010-10-07 |
20100255020 | METHOD FOR INDUCING CYTOTOXIC T-CELLS, CYTOTOXIC T-CELL INDUCERS, AND PHARMACEUTICAL COMPOSITIONS AND VACCINES EMPLOYING THEM - A method for inducing cytotoxic T-cells is provided that includes binding to an HLA molecule on the surface of a cell that is a target of a cytotoxic T-cell, a peptide containing one or more types of amino acid sequence selected from the group consisting of SEQ ID NOS: 1, 2, and 3 and composed of not less than 8 and not more than 11 amino acid residues, or a peptide derived from a precursor thereof. | 2010-10-07 |
20100255021 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 6 - The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections. | 2010-10-07 |
20100255022 | VACCINE AGAINST CLOSTRIDIUM PERFRINGENS - There is provided a vaccine for controlling | 2010-10-07 |
20100255023 | DENDRITIC CELL VACCINE COMPOSITIONS AND USES OF SAME - The present invention provides adjuvants, vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The compositions and methods are useful for generating immune responses against antigens, including microbial pathogens and tumor-associated antigens, by way of inhibiting a negative immune regulator in a cell and providing a proinflammatory stimulus. In particular, nucleotides encoding inhibitors of negative immune regulators, antigens, and co-stimulatory molecules are contacted with immune cells in order to elicit a therapeutic or prophylactic response. | 2010-10-07 |
20100255024 | COMPOSITION FOR INHIBITION OF TRANSPLANT REJECTION CONTAINING THE PHELLINUS LINTEUS MYCELLIA EXTRACT AS AN ACTIVE INGREDIENT - Disclosed is a composition for the inhibition of transplant rejection and the prevention and treatment of skin diseases, comprising a | 2010-10-07 |
20100255025 | COMPOSITIONS OF MARINE BOTANICALS TO PROVIDE NUTRITION TO AGING AND ENVIRONMENTALLY DAMAGED SKIN - The present invention relates to methods and compositions comprising marine botanicals for treating aged, mature, nutritionally-compromised, or environmentally-damaged skin. These methods and compositions provide improvements in the skin's visual appearance, physiological functions, clinical properties, and biophysical properties. | 2010-10-07 |
20100255026 | Methods and compositions relating to anthrax spore glycoproteins as vaccines - Disclosed are methods for preparing an anthrax spore glycoprotein complex vaccine. Also, disclosed compositions of an anthrax vaccine including a spore glycoprotein complex as the active agent. In certain embodiments, the vaccines are sufficient to protect against infection from | 2010-10-07 |
20100255027 | Papilloma pseudovirus and preparation - The invention involves a papilloma pseudovirus that can induce immune response after oral intake as well as its preparation. It is characterized in that HPV or BPV pseudovirus are made by disrupting HPV-VLP or BPV-VLP, mixing them with plasmids (plasmids or DNA vaccine), and reassembling them into the pseudoviruses (VLPs with plasmids inside). Oral administration of the pseudoviruses will result in delivery to mucosal and systemic lymphoid tissues and induce immune responses for disease prevention and treatment. The pseudovirus induces stronger immune response than DNA vaccines. Additionally, the pseudovirus can be applied in gene therapy by bringing the therapeutic genes into lymphoid tissues in the human body. | 2010-10-07 |
20100255028 | Flavivirus Vaccine Vector Against Influenza Virus - This invention relates to chimeric flavivirus vectors that can be used, for example, in the prevention and treatment of influenza virus infection, compositions including such viral vectors, and methods employing the vectors. | 2010-10-07 |
20100255029 | NEWCASTLE DISEASE VIRUS VECTORED AVIAN VACCINES - The present invention encompasses engineered Newcastle Disease Virus (NDV) vaccines or compositions. The vaccine or composition may be a recombinant vaccine. The invention also encompasses recombinant vectors encoding and expressing avian pathogen antigens, more specifically avian influenza proteins, epitopes or immunogens. Such vaccines or compositions can be used to protect animals, in particular avian, against disease. | 2010-10-07 |
20100255030 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 2010-10-07 |
20100255031 | TRUNCATED L1 PROTEIN OF HUMAN PAPILLOMAVIRUS TYPE 16 - The invention relates to a truncated L1 protein of the Human Papillomavirus Type 16, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer. | 2010-10-07 |
20100255032 | Parapoxviruses in combination with other antiviral agents for the treatment of viral diseases - The present invention relates to the use of | 2010-10-07 |
20100255033 | Non-toxic double mutant forms of pertussis toxin as adjuvants - The invention relates to the use of an antigen which is a non-toxic double mutant form of pertussis toxin for the manufacture of a vaccine composition for intranasal administration to induce an immune response against | 2010-10-07 |
20100255034 | Streptococcus Pyogenes Antigens - The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from | 2010-10-07 |
20100255035 | Modified live (JMSO strain) Haemophilus parasuis vaccine - The present invention is a culture of cells of | 2010-10-07 |
20100255036 | ATTENUATED FNR DEFICIENT ENTEROBACTERIA - The invention provides an attenuated enterobacterium comprising an attenuating mutation in the fnr gene, and optionally further comprising a heterologous nucleic acid encoding a foreign antigen. Also provided are pharmaceutical formulations comprising the attenuated enterobacteria of the invention. Further disclosed are methods of inducing an immune response in a subject by administration of an immunogenically effective amount of an attenuated enterobacterium or pharmaceutical formulation of the invention. | 2010-10-07 |
20100255037 | NOVEL SEQUENCES OF HAEMONCHUS CONTORTUS, IMMUNOGENIC COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF - The present invention relates to novel sequences of | 2010-10-07 |
20100255038 | PURIFIED POLYPEPTIDE COMPRISING OR CONSISTING OF A C-TERMINUS MSP1 ANTIGEN FROM PLASMODIUM FALCIPARUM CARRYING A GLYCOSYL-PHOSPHATIDYL-INOSITOL GROUP (GPI) - The present invention relates to a purified polypeptide comprising or consisting of a C-terminus MSP1 antigen from | 2010-10-07 |
20100255039 | INDUCTION OF TOLERANCE TO EGG PROTEINS - The use of enzymatically hydrolysed egg proteins with a degree of hydrolysis between 15 and 28% in the manufacture of a composition for induction of oral tolerance to egg proteins in a mammal. | 2010-10-07 |
20100255040 | COMPOSITION FOR IMPROVING TLR-MEDIATED CELLULAR IMMUNITY COMPRISING POLY-GAMMA-GLUTAMIC ACID - The present invention relates to a composition for improving cellular immunity, which comprises an effective dose of poly-gamma-glutamic acid, and more particularly, to a composition for improving cellular immunity comprising poly-gamma-glutamic acid, which has effects of inducing enhancement of TLR-mediated Th1 cellular immunity and improving antigen presenting activity to maintain the improved activity. The inventive composition comprising an effective dose of poly-gamma-glutamic acid has very little toxicity and side effects, and can be added to a vaccine composition for preventing and treating animal viral or bacterial infections and cancer, or a vaccine composition for preventing and treating human viral or bacterial infections and cancer to show cellular immunity-enhancing effects. | 2010-10-07 |
20100255041 | REMEDY FOR THE TREATMENT OF CARDIO-VASCULAR DISEASES OR DISORDERS - Disclosed is the use of inhibitors of β-catenin expression or activity or modulators downregulating β-catenin expression or activity for the treatment of cardiovascular diseases or disorders and their use in the treatment of cardiovascular diseases and disorders, such as heart failure syndrome. The use of those agents resulted in particular in cardiomyocyte differentiation of endogenous cardiac stem cells. | 2010-10-07 |
20100255042 | Process for Producing Particles Loaded with Growth Factors as Well as the Particles Thus Obtained - The present invention refers to a process for preparing a particulate material (particles) being loaded with growth factors, the thus obtained particles and the use for improving the ingrowth of implant material into the bone substance. | 2010-10-07 |
20100255043 | Methods for preparing T-cells for cell therapy - T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities. | 2010-10-07 |
20100255044 | METHOD OF DEPOSITING PARTICULATE BENEFIT AGENTS ON KERATIN-CONTAINING SUBSTRATES - This invention relates to the deposition of particulate benefit agents onto keratin-containing substrates such that the deposited particulates are resistant to removal by exposure to surfactants or cleansing agents. The deposition is accomplished by sequentially treating the substrate with a cationic composition followed by treatment with an anionic particulate benefit agent. | 2010-10-07 |
20100255045 | COMPOSITION FOR PHOTODYNAMIC SKIN TREATMENT - The invention relates to a composition for photodynamic therapy. The composition of the invention, in the form of a gel or a cross-linked hydrogel, includes a chlorophyll photosensitising substance or a derivative thereof, in particular chlorophyllin optionally associated with an additional ingredient such as an alpha- or beta-hydroxy acid, a depigmentation or lightening agent, and/or an antioxidant. The invention can be used in the treatment of skin aging signs and in skin regeneration. | 2010-10-07 |
20100255046 | COSMETIC POWDER COATED WITH ALKOXY SILICONES - A cosmetic powder, endowed with a hydrophobic coating based on alkoxy silicones, comprising a powder phase and a hydrophobic coating phase, said hydrophobic coating phase completely coats said powder phase and said coating phase consists of a compound of general formula (RO) | 2010-10-07 |
20100255047 | EFFECT PIGMENTS BASED ON COATED GLASS FLAKES - The present invention relates to effect pigments based on thin glass flakes and to a method for the production of such pigments. The resulting pigment can be used in any application for which pearlescent pigments have been heretofore used such as, for example, in plastics, paints, inks, cosmetic formulations, coatings including solvent or waterborne automotive paint systems, powder coatings, inks and agriculture foils. | 2010-10-07 |
20100255048 | Web Material - A web material encompasses a bonded fibrous material web of cellulose material that is made of a layer of cellulose fibers that are press-bonded in sections of the fibrous material web. One or several antimicrobial substances are contained in the fibrous material web. The antimicrobial substances are selected from finely dispersed silver and silver salts, antimicrobial metal oxides, solid inorganic acids, solid organic acids, and biocides. | 2010-10-07 |
20100255049 | Eco-friendly antibacterial and mildew-inhibited freshness preserving sheet - An eco-friendly, antibacterial and mildew-inhibited freshness preserving sheet containing volatile and high concentration molecules of Ally isothiocyanate is formed by absorbing all ingredients of anti-mold and eco-friendly antibacterial material through a closed fumigation permeation method until saturated. The sheet has a substrate and a jutting text and pattern layer formed by heated embossing with a zinc plate. The embossed sheet is fumigated by a fumigator containing natural anti-mold and antiseptic material to absorb the ingredients of the natural anti-mold and antiseptic material to become a finished product. The natural anti-mold and antiseptic material includes gradients of Ally isothiocyanate 35% by weight, ploysorbate 5% by weight and natural coconut oil 60% by weight. | 2010-10-07 |
20100255050 | Polyethylene Based Bioactive Agents - The present invention concerns an acyclic diene metathesis (ADMET) chemistry-based method of making polymers incorporating biologically active molecules, and the polymers formed thereby. Functionalized polymers prepared by this method can be used to produce a broad range of commercially important products such as drag delivery agents (prodrugs), chromatography reagents (e.g., for use in separatory reagents), biomimetics, and biodegradable synthetic polymers. | 2010-10-07 |
20100255051 | POLYKETAL POLYMERS, AND METHODS OF MAKING AND USING SAME - Polyketal polymers, and methods of making and using such polyketal polymers are disclosed herein. The polyketal poylmers can be useful for applications including, for example, medical devices and pharmaceutical compositions. In a preferred embodiment, the polyketal polymers are biodegradable. | 2010-10-07 |
20100255052 | INTEGRATED IMPLANT SYSTEM (IIS) BIOCOMPATIBLE, BIODEGRADABLE AND BIOACTIVE, COMPRISING A BIOCOMPATIBLE STERILE POROUS POLYMERIC MATRIX AND A GEL, INTEGRATING IN SITU THE TRIDIMENSIONAL MATRIX STRUCTURE - The present invention refers to an Integrated Implant System constituted as a gel-matrix-cells integrated system, that allows providing implants in a brief time period, for covering a great skin extension to be treated, with a successful acceptance in patients with burns, chronic damage or wound skin, needing of a skin grafting. | 2010-10-07 |
20100255053 | MEDICAL IMPLANT WITH BIOACTIVE MATERIAL AND METHOD OF MAKING THE MEDICAL IMPLANT - Embodiments of the invention include a medical device and a method of manufacturing a medical device having a porous scaffold in combination with a bioactive material. In some embodiments, particularly limited thicknesses of the bioactive material are applied within pores of the porous structure. | 2010-10-07 |
20100255054 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF RESTENOSIS - Provided is a pharmaceutical composition for the treatment and/or prevention of restenosis including (a) a therapeutically effective amount of a particular compound represented by Formula 1 and 2, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. | 2010-10-07 |
20100255055 | GOLD-COATED STENT COATED/PLATED THE CHEMICALS AND OLIGONUCLEOTIDE BINDING GOLD-COATED STENT AND PROCESS FOR PRODUCING THE SAME - The present invention relates to a gold-plated stent and its preparation method. More specifically, it relates to a gold-plated stent that is coated with various chemical materials such as 2-aminoalkanethiol, epihalogenhydrin, and diamine compounds in a sequence and also oligonucleotide gold-plated stent, which is prepared by binding oligonucleotide, a biomaterial, to the gold-plated stent coated with said chemicals. The oligonucleotide gold-plated stent of the present invention has an advantages of raising the local concentration in injured parts and minimizing the toxicity overall the body, so it can be used for prevention of restenosis after angioplasty. | 2010-10-07 |
20100255056 | Fibronectin Type III Domain Based Scaffold Compositions, Methods And Uses - A protein scaffold based on a consensus sequence of the tenth fibronectin type III (FN3) repeat from human fibronectin, including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG based on the consensus sequence have been identified as useful for diagnostic and/or therapeutic applications. | 2010-10-07 |